{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016112","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.471941+00:00","generated_at":"2026-06-02T02:24:34.723206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Moleculin Q1 cash $16.8M; Annamycin CRc 62% in 1st/2nd line AML","bullets":["R&D expense $4.3M, G&A $2.4M; cash $16.8M expected to fund operations into Q4 2024.","MB-106 trial: 20 subjects evaluated; 45% CRc all lines (N=20); 62% CRc in 1st/2nd line (N=13).","USPTO issued patent for liposomal Annamycin composition; EMA granted Orphan Drug Designation for AML.","End of Phase 2 FDA meeting expected H1 2024; pivotal trial initiation planned H1 2025; NDA submission potential 2027.","Formed Annamycin Scientific Advisory Board with Dr. Martin Tallman as inaugural member."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016112","json":"https://secwatch.observer/filing/0001437749-24-016112.json","markdown":"https://secwatch.observer/filing/0001437749-24-016112.md","text":"https://secwatch.observer/filing/0001437749-24-016112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774924016112/0001437749-24-016112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774924016112/mbrx20240509_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:24:34.723206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d97e73124b62a74e6b1f53f71d5fa97de425033c","claim":"Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 13, 2024, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and recent operational highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774924016112/0001437749-24-016112-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}